Atlas Trials

Advanced Gastric Adenocarcinoma

22 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Advanced Gastric Adenocarcinoma

RecordFirmDate
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab (NCT05583383)Henan Cancer Hospital2022-03-31
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153)M.D. Anderson Cancer Center2022-02-14
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC (NCT06238752)Renmin Hospital of Wuhan University2021-03-01
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer (NCT04675866)Henan Cancer Hospital2020-08-17
Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy (NCT04993378)Shen Lin2018-11-01
Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment (NCT02447380)Samsung Medical Center2017-07-10
Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma (NCT03159819)Changhai Hospital2017-04-01
Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment (NCT02449551)Samsung Medical Center2016-02-10
PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma (NCT02615730)Yonsei University2016-02-01
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (NCT02599324)Pharmacyclics LLC.2015-12-01
Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment (NCT02447406)Samsung Medical Center2015-04-30
Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy (NCT02449655)Samsung Medical Center2015-02-12
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy (NCT02448329)Samsung Medical Center2015-01-14
Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer (NCT02240524)Affiliated Cancer Hospital & Institute of Guangzhou Medical University2014-07-01

Track Advanced Gastric Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.